Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 9/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 3/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482460 | 1.00 | TSHR (1.00) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL13283404 | 1.00 | TSHR (1.00) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL322713 | 1.00 | TSHR (1.00) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL3503091 | 1.00 | TSHR (1.00) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL20873747 | 1.00 | TSHR (1.00) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL33725 | 1.00 | TSHR (1.00) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL8493780 | 1.00 | TSHR (1.00) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL13945622 | 1.00 | TSHR (1.00) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL9101988 | 1.00 | TSHR (1.00) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL29601936 | 1.00 | TSHR (1.00) | TSHRALDH1A1CYP3A4HPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728339-B1 | COMPOSITION FOR OPHTHALMOLOGICAL PRODUCTS | AMO Ireland (IE) | 2022-07-06 | — | — | EP | claimed |
| US-11359031-B2 | Composition for ophthalmological products | Johnson & Johnson Surgical Vision, Inc. (US) | 2022-06-14 | — | — | US | claimed |
| EP-4182737-B1 | OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2024-07-03 | — | — | EP | disclosed |
| US-20240142665-A1 | OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2024-05-02 | — | — | US | disclosed |
| US-20240117092-A1 | OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2024-04-11 | — | — | US | disclosed |
| EP-4284787-A1 | OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-12-06 | — | — | EP | disclosed |
| EP-4263513-A1 | OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-10-25 | — | — | EP | disclosed |
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230273456-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
| EP-4182736-A1 | OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-05-24 | — | — | EP | disclosed |
| EP-4182737-A1 | OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-05-24 | — | — | EP | disclosed |
| EP-4036085-A1 | COMPOUNDS FOR OPTICALLY ACTIVE OPHTHALMIC DEVICES | AMO Ireland (IE) | 2022-08-03 | — | — | EP | disclosed |
| EP-3728339-B1 | COMPOSITION FOR OPHTHALMOLOGICAL PRODUCTS | AMO Ireland (IE) | 2022-07-06 | — | — | EP | disclosed |
| WO-2022128832-A1 | OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2022-06-23 | — | — | WO | disclosed |
| EP-4015512-A1 | OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2022-06-22 | — | — | EP | disclosed |
| US-11359031-B2 | Composition for ophthalmological products | Johnson & Johnson Surgical Vision, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230273456-A1 | OPTICALLY ACTIVE DEVICES | PDE6C, PDE6D, PDE6A | TSHR 4585/4885ALDH1A1 277/4885CYP3A4 2508/4885 |
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | PDE6C, PDE6A, PDE6D | TSHR 4592/4885ALDH1A1 311/4885CYP3A4 2513/4885 |
| US-20240117092-A1 | OPTICALLY ACTIVE DEVICES | PDE6C, UACA, PDE6A | TSHR 4604/4885ALDH1A1 538/4885CYP3A4 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.